Elan Pharmaceuticals, Inc.

Redwood Bioscience, Inc.

Imago Pharmaceuticals, Inc.

An2h Discovery Limited

Escape Bio, Inc.

Redwood Biosciences, Inc.

Albert W Garofalo

David Rabuka

Aaron Edward Albers

Romas Alvydas Kudirka

Darren B Dressen

Jing Wu

Simeon Bowers

Andrei William Konradi

Christopher Michael Semko

Anh P Truong

Martin Neitzel

Jesse M McFarland

Michael A Pleiss

Jay S Tung

Ying-Zi Xu

Roy K Hom

R Jeffrey Neitz

Robyn M Barfield

Gregory W deHart

Penelope M Drake

Matthew N Mattson

Ashley C Guinn

Xiaocong Michael Ye

David W G Wone

Gary D Probst

Jennifer Marugg

Paul Ross Fatheree

Lee H Latimer

Jacob Bradley Schwarz

John Alan Tucker

Minghua Sun

Jenifer Lea Smith

Daniele Andreotti

Michael S Dappen

Stéphane De Lombaert

Danielle Aubele

Marc Adler

Jennifer Johnston

Jennifer Sealy

Fabio Maria Sabbatini

Scott A Jenkins

Raymond Ng

Claudia Beato

Silvia Bernardi

Danielle L Aubele

Maurizio Franzini

Federica Budassi

Marco Migliore

Elena Serra

Jacek J Jagodinski

Jesse M Mcfarland

Gregory W Dehart

The present disclosure provides conjugate structures and hydrazinyl-pyrrolo compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

Hydrazinyl-pyrrolo compounds and methods for producing a conjugate

The present disclosure provides anti-HER2 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

Anti-HER2 antibody-maytansine conjugates and methods of use thereof

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

Indazoles and azaindazoles as LRRK2 inhibitors

The present disclosure is directed to triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R, R, R, M, M, M, L, L, and Lare as defined herein. 

Triazole benzamide derivatives and the compositions and methods of treatment regarding the same

The present invention provides compounds having a structure according to Formula I: (I) or a salt or solvate thereof, wherein R1, R2, R3 and R4 are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease. 

Substituted cinnolines as inhibitors of LRRK2 kinase activity

The current invention provides compounds having a structure according to Formulae 1, 2, 3, and 4: wherein the A-ring, B-ring, C-ring, m, n, R, R, and Rare as described in the specification. The invention also provides pharmaceutical compositions comprising compounds of Formulae 1, 2, 3, and 4, as well as methods of treating cognitive disorders, such as Alzheimer's disease. The invention further provides intermediates useful in preparing the compounds of Formulae 1, 2, 3, and 4.

N-sulfonamido polycyclic pyrazolyl compounds

The invention provides compounds of Formula I wherein A, Y, R, R, R, and Rare as described in the specification. Compounds of Formula I are useful in treating and/or preventing cognitive disorders, such as Alzheimer's disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of preparing compounds of Formula I, and methods of treating cognitive disorders, such as Alzheimer's disease.

Pyrazolopyrrolidines as inhibitors of gamma secretase

This invention is directed to acylated amino acid amidyl pyrazoles and related compounds of Formula I. The invention is also directed to a pharmaceutical formation comprising such compound or in a pharmaceutically acceptable salt form thereof. The invention is further directed to a method for inhibiting &#x3b2;-amyloid peptide release and/or synthesis, a method for inhibiting &#x3b3;-secretase activity, and a method for treating neurological disorders associated with &#x3b2;-amyloid peptide production. The method comprises administering to a host a pharmaceutical formulation comprising an effective amount of a compound of Formula I. The compounds of Formula I are useful in the prevention and treatment of Alzheimer's disease.

Acylated amino acid amidyl pyrazoles and related compounds

The invention provides N-cyclic sulfonamido compounds and salts of Formula I:  wherein A is as described in the specification and Rand Rcombine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula I.

Bridged N-cyclic sulfonamido inhibitors of gamma secretase

Growing community of inventors

South San Francisco, CA, United States of America

Albert W Garofalo